Therapy: Are TNF blockers safe for patients with hepatitis B virus infection?
Ramos-Casals
Manuel
M
Institut d'Investigacions Biomèdiques August Pi i Sunyer, Department of Autoimmune Diseases, Laboratory of Autoimmune Diseases Josep Font, Villarroel 170, Barcelona 08036, Spain. mramos@clinic.ub.es
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000502:physiology; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D012216:Rheumatic Diseases / Q000188:drug therapy*; D012307:Risk Factors; D055502:Secondary Prevention; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D014409:Tumor Necrosis Factor-alpha